A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT05106335
Phase
PHASE3
Status
Terminated

Conditions

  • Advanced NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • camrelizumab + famitinib — DRUG
    camrelizumab for intravenous injection; famitinib malate capsules for oral administration
  • famitinib — DRUG
    famitinib malate capsules for oral administration
  • docetaxel — DRUG
    docetaxel for intravenous injection

Study Details

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.

Key Dates

Start date
Jan 6, 2022
Status verified
Aug 2023
Primary completion
May 11, 2022
Completion
May 11, 2022

Study Design

Enrollment
1 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm A
    camrelizumab + famitinib
  • Experimental: Treatment Arm C
    famitinib
  • Active Comparator: Treatment Arm B
    docetaxel

Primary Outcome Measure

OS [ Time Frame: up to 4 years ]

Related Studies